10-Q: Absci Corp Reports Q3 2026 Results, Faces Revenue Dip

Absci Corporation's Q3 2026 filing reveals a continued net loss and declining partner program revenue, though R&D expenses increased to support pipeline advancement.

Summary

• Absci Corporation reported a net loss of $33.3 million for the three months ended September 30, 2026, and $96.1 million for the nine months ended September 30, 2026.
• Partner program revenue decreased to $0.3 million for the three months and $0.8 million for the nine months ended September 30, 2026, compared to $0.4 million and $2.2 million in the prior year periods.
• Research and development expenses increased by 22% to $23.6 million for the three months and 17% to $65.5 million for the nine months ended September 30, 2026.
• The company had $173.7 million in cash, cash equivalents, and marketable securities as of September 30, 2026, which it believes is sufficient for at least the next 12 months.
• The company is advancing its lead product candidate, ABS-201, for pattern hair loss and endometriosis, with interim Phase 1 data showing favorable tolerability and an estimated half-life of at least 65 days.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative score due to continued net losses, declining revenue, and significant ongoing expenses, despite progress in clinical development and strategic collaborations.

Positives

• Positive interim Phase 1 data for ABS-201 in the HEADLINE trial for pattern hair loss, indicating good tolerability and a favorable safety profile.
• Estimated half-life of at least 65 days for ABS-201, supporting a potential patient-friendly dosing interval.
• Strategic collaboration with AMD, including a $20 million investment, aimed at optimizing AI drug creation models.
• Company believes its current cash, cash equivalents, and marketable securities are sufficient to meet operating needs for at least the next 12 months.
• Advancement of early-stage immunology and inflammation programs using the AI-native platform.

Negatives

• Continued significant net losses, with a $33.3 million loss in Q3 2026 and $96.1 million loss for the nine months ended September 30, 2026.
• Declining partner program revenue, down 20% for the quarter and 61% for the nine months compared to the prior year.
• Increased research and development expenses, up 22% for the quarter and 17% for the nine months, indicating higher burn rate.
• Accumulated deficit of $720.9 million as of September 30, 2026.
• Dependence on future capital raises, with a risk of dilution or unfavorable terms if additional financing is needed.

Risks

• High degree of uncertainty regarding the initiation, timing, progress, results, and costs of internally developed programs and clinical trials.
• Inability to raise additional capital on acceptable terms, which could hinder operations and development.
• Biologic drug development is inherently uncertain, with no guarantee that product candidates will achieve development or regulatory milestones.
• Reliance on third parties for nonclinical studies and clinical trials, with risks of performance failures or premature termination.
• Intense competition in the markets for Integrated Drug Creation platform technology and internally developed programs.
• Potential for delays in clinical development, regulatory approval, or commercialization of product candidates.
• The market may be skeptical of the viability and benefits of the AI-native platform due to its novelty.
• The company has incurred significant losses since inception and expects to continue incurring losses in the future.

Future Outlook

The company expects to continue incurring significant expenses for developing ABS-201 and other internally developed programs, scaling its platform through partnerships, and acquiring new technologies. Management believes current cash, cash equivalents, and marketable securities are sufficient for at least the next 12 months, but future capital requirements will depend on various factors, including the ability to raise additional capital.

Management Comments

• We believe PRLR is an underexplored target with the potential to provide durable, disease-modifying effects.
• This combination of underexplored target selection and capital-efficient execution is central to our strategy.
• We expect research and development expenses to continue to increase in absolute dollars as we advance the HEADLINE trial, prepare for and conduct later stage trials in pattern hair loss, prepare for and conduct the planned Phase 2 STORYLINE trial, advance our other internally developed programs, and continue to invest in our Integrated Drug Creation platform.

Industry Context

StockSavvy.ai notes that Absci operates in the highly competitive biopharmaceutical sector, focusing on AI-driven drug discovery. The company's strategy of leveraging its Integrated Drug Creation platform for both internal programs and partnerships is common, but success hinges on demonstrating the platform's efficacy and advancing candidates through the lengthy and costly drug development process.

Comparison to Industry Standards

• Absci highlights that its programs have advanced from AI design to IND (or foreign equivalent) in approximately 2 years with a total investment of $15 million per program, compared to an industry average of 4-6 years at a cost of over $50 million.
• The company aims to address unmet medical needs in areas with low competition, a strategy employed by many biopharmaceutical firms.
• The development timelines and costs mentioned are significantly lower than typical industry averages for biologic drug development, suggesting potential efficiency gains from their AI platform.

Legal Proceedings

• The company is not currently a party to any material litigation or other legal proceedings.

Related Party Transactions

• Strategic collaboration with Advanced Micro Devices, Inc. (AMD) involving a $20.0 million investment through a private investment in public equity (PIPE) at a premium over market price.

Stakeholder Impact

• Shareholders may experience dilution if additional capital is raised through equity offerings.
• Continued net losses and reliance on future financing could impact investor confidence and stock price.
• Partners may be impacted by the company's ability to deliver on its platform technology and advance programs.
• Employees may be impacted by the company's need to manage growth and potentially restructure operations.

Next Steps

• Interim proof-of-concept data for ABS-201 in the HEADLINE trial are expected in December 2026.
• Full proof-of-concept data for ABS-201 in the HEADLINE trial are expected in early 2027.
• Initiation of the Phase 2 STORYLINE trial for endometriosis is anticipated in mid-2027.
• Continued investment in the Integrated Drug Creation platform and advancement of early-stage programs.
• Seeking partnerships or out-licenses for select early-stage programs.

Key Dates

Recommendation

Absci Corporation's Q3 2026 filing presents a mixed picture. While the company is making progress in its clinical development with positive interim data for ABS-201 and advancing its AI platform, the significant increase in net losses and decline in revenue are concerning. The company's substantial cash reserves provide a near-term runway, but its long-term success remains contingent on future financing and the successful commercialization of its pipeline, which carries inherent risks. Therefore, a 'hold' recommendation is appropriate, pending further clinical data and a clearer path to profitability.

Keywords

AI drug creation, biopharmaceutical, clinical-stage, antibody therapeutics, Integrated Drug Creation platform, ABS-201, pattern hair loss, endometriosis